Protagonist Therapeutics Inc (PTGX) — Cash Flow-to-Debt Ratio
Protagonist Therapeutics Inc (PTGX) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of $-1.94 Million could theoretically repay 0% of its total liabilities ($56.25 Million) in one year. Explore PTGX long-term investments to assets to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Protagonist Therapeutics Inc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Protagonist Therapeutics Inc across 11 annual periods. Also explore PTGX asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Protagonist Therapeutics Inc (2014–2024)
Year-by-year debt coverage analysis for Protagonist Therapeutics Inc. For market capitalisation and broader financial context, see PTGX stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 2.65x | $184.15 Million | $69.43 Million | ▲ +180.3% |
| 2023 | -3.30x | $-70.24 Million | $21.27 Million | ▲ +1.3% |
| 2022 | -3.35x | $-108.14 Million | $32.32 Million | ▼ -47.9% |
| 2021 | -2.26x | $-107.86 Million | $47.67 Million | ▼ -40.0% |
| 2020 | -1.62x | $-72.48 Million | $44.86 Million | ▼ -191.6% |
| 2019 | -0.55x | $-41.53 Million | $74.95 Million | ▲ +70.1% |
| 2018 | -1.85x | $-49.95 Million | $26.96 Million | ▼ -2162.5% |
| 2017 | 0.09x | $3.87 Million | $43.10 Million | ▲ +101.9% |
| 2016 | -4.66x | $-29.97 Million | $6.43 Million | ▼ -70.0% |
| 2015 | -2.74x | $-14.38 Million | $5.25 Million | ▲ +16.0% |
| 2014 | -3.26x | $-7.74 Million | $2.37 Million | — |